- Home
- All Stock List
- NSE
- Procter & Gamble Health Ltd Share Price
Procter & Gamble Health Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
-
3
Like
-
Share
-
Feedback
5,146.50
143.90 (2.88%)
-
Outperforms Index
9.27%
Return (1Y)
Beaten Nifty 50 by 3.93%
-
More Volatile
1.58%
Standard Deviation (1Y)
Higher than Nifty 50 by 0.7%
-
Consistent Performer
7/12
Months
beaten Nifty 50
-
AxisDirect View
No View
5,850
4,637
News & Announcements
-
-
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 309.77 309.97 0 OPM % 39.85 32.79 - PBDT 127.24 106.64 19 PBT 121.69 99.72 22 NP 90.90 72.07 26 Powered by Capital Market - Live News
-
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 309.77 309.97 0 OPM % 39.85 32.79 - PBDT 127.24 106.64 19 PBT 121.69 99.72 22 NP 90.90 72.07 26 Powered by Capital Market - Live News
-
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
47 days ago
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
12 - Feb - 2025 12:00 | 47 days ago
The company’s revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year.
Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review.
Milind Thatte, Managing Director, P&G Health India, said, “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network.
We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”
Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025.
Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.
Powered by Capital Market - Live News
-
-
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 309.77 309.97 0 OPM % 39.85 32.79 - PBDT 127.24 106.64 19 PBT 121.69 99.72 22 NP 90.90 72.07 26 Powered by Capital Market - Live News
-
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
47 days ago
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
12 - Feb - 2025 12:00 | 47 days ago
The company’s revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year.
Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review.
Milind Thatte, Managing Director, P&G Health India, said, “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network.
We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”
Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025.
Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.
Powered by Capital Market - Live News
-
-
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 309.77 309.97 0 OPM % 39.85 32.79 - PBDT 127.24 106.64 19 PBT 121.69 99.72 22 NP 90.90 72.07 26 Powered by Capital Market - Live News
-
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
12 - Feb - 2025 12:00 | 47 days ago
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 309.77 309.97 0 OPM % 39.85 32.79 - PBDT 127.24 106.64 19 PBT 121.69 99.72 22 NP 90.90 72.07 26 Powered by Capital Market - Live News
-
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
-
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
47 days ago
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
12 - Feb - 2025 12:00 | 47 days ago
The company’s revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year.
Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review.
Milind Thatte, Managing Director, P&G Health India, said, “This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network.
We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.”
Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025.
Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Merck Ltd has increased by 6.17% since past 3 Months
MF shareholding in Merck Ltd has increased by 18.41% since past 1 Year
FII shareholding in Merck Ltd has increased by 6.17% since past 3 Months
FII shareholding in Merck Ltd has decreased by -7.63% since past 1 Year
MF shareholding in Merck Ltd has increased by 18.41% since past 1 Year
FII shareholding in Merck Ltd has increased by 6.17% since past 3 Months
MF shareholding in Merck Ltd has increased by 18.41% since past 1 Year
